Search

Your search keyword '"Clauser, Karl R."' showing total 409 results

Search Constraints

Start Over You searched for: Author "Clauser, Karl R." Remove constraint Author: "Clauser, Karl R."
409 results on '"Clauser, Karl R."'

Search Results

1. The HLA-II immunopeptidome of SARS-CoV-2

2. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma

3. Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues

4. Deep learning integrates histopathology and proteogenomics at a pan-cancer level

5. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation

6. Pan-cancer proteogenomics connects oncogenic drivers to functional states

7. Proteogenomic data and resources for pan-cancer analysis

12. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer

13. Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs

14. Site-specific identification and quantitation of endogenous SUMO modifications under native conditions.

15. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma

16. Noncanonical open reading frames encode functional proteins essential for cancer cell survival

17. Abstract A038: Non-canonical MHC class I-associated antigens in pancreatic cancer

18. Glyco-centric lectin magnetic bead array (LeMBA) - proteomics dataset of human serum samples from healthy, Barrett׳s esophagus and esophageal adenocarcinoma individuals.

20. A large peptidome dataset improves HLA class I epitope prediction across most of the human population

22. Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics

24. Author Correction: Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics

26. Pan-viral ORFs discovery using Massively Parallel Ribosome Profiling

27. Deep learning integrates histopathology and proteogenomics at a pan-cancer level

28. Pan-cancer proteogenomics connects oncogenic drivers to functional states

29. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation

30. Proteogenomic data and resources for pan-cancer analysis

31. Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells.

32. Microscaled proteogenomic methods for precision oncology

33. Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography–mass spectrometry

34. Figure 1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases

35. Supplementary Data from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases

36. The HLA-II immunopeptidome of SARS-CoV-2

38. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma

39. Proteomic profiling of extracellular matrix components from patient metastases identifies consistently elevated proteins for developing nanobodies that target primary tumors and metastases

40. The HLA-II immunopeptidome of SARS-CoV-2

41. Supplementary File 5 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

42. Supplementary File 1 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

43. Supplementary File 2 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

44. Extended Methods from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

45. Supplementary File 3 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

46. Supplementary Figures from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

47. Supplementary tables 1 and 2 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

48. Data from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

49. Supplementary File 4 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

Catalog

Books, media, physical & digital resources